How KLHL6 loss affects B‑cell lymphoma
Role of KLHL6 inactivation in mature B-cell malignancies
This work looks at whether losing the KLHL6 gene drives aggressive diffuse large B‑cell lymphoma and changes how patients respond to treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11234310 on NIH RePORTER |
What this research studies
If I or a loved one has diffuse large B‑cell lymphoma (DLBCL), this project tries to understand whether loss of the KLHL6 gene makes the cancer grow faster or become treatment resistant. Researchers will create mouse models that lack Khll6 and grow patient-derived DLBCL tumors in mice to see how tumors behave when KLHL6 is impaired. The team will study KLHL6's role in the ubiquitin ligase system and NOTCH signaling and test whether blocking the B‑cell receptor works differently when KLHL6 is lost. Lab and mouse findings aim to point to pathways that could be targeted for new therapies in the future.
Who could benefit from this research
Good fit: Adults with diffuse large B‑cell lymphoma, especially those with KLHL6 mutations or relapsed/refractory disease, would be the most relevant group.
Not a fit: People without DLBCL or without KLHL6-related changes are unlikely to get direct benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could identify new drug targets in the ubiquitin/NOTCH pathways or help predict who might benefit from B‑cell receptor inhibitors.
How similar studies have performed: Drugs that target the ubiquitin system (for example bortezomib and newer E3 ligase strategies) have worked in blood cancers, but targeting KLHL6 itself is a newer and less-tested idea.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Busino, Luca — University of Pennsylvania
- Study coordinator: Busino, Luca
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.